2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow Andrew Ko: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma PEGPH20, Gemcitabine, Nab-paclitaxel - Adenocarcinoma | Phase 2 | Terminated | Andrew Ko | 3 | 2015-07-14 | 2020-01-02 |
| Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer S-1, gemcitabine hydrochloride - Pancreatic Cancer | Phase 2 | Terminated | Andrew Ko | 21 | 2007-01-22 | 2020-09-18 |
Adenocarcinoma (1) · Pancreatic Neoplasms (1)
Gemcitabine (2) · 130-nm albumin-bound paclitaxel (1) · PEGPH20 (1) · S 1 (combination) (1) · titanium silicide (1)
United States (2)